# OnCo record kymera (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kymera/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kymera" ;
  schema:name "Kymera Therapeutics"@en ;
  schema:description "Oral degrader company, mostly immunology, whose CDK2 molecular-glue degrader was optioned by Gilead in 2026 for CCNE1-driven cancers."@en ;
  schema:url <https://onco.cc/companies/kymera/>, <https://www.kymeratx.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.fiercebiotech.com/biotech/gilead-pays-kymera-45m-glue-preclinical-protein-degrader-burgeoning-oncology-pipeline> ;
  schema:addressCountry "US" ;
  onco:related <https://onco.cc/collections/src-fierce-biotech/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:companies <https://onco.cc/companies/gilead/> .